Short Note
Version 1
Preserved in Portico This version is not peer-reviewed
1-(3-(2-(Dimethylammonio)ethyl)-1H-indol-5-yl)- N-Methylmethanesulfonamide Succinate Hemi(Ethanol Solvate)
Version 1
: Received: 11 December 2023 / Approved: 12 December 2023 / Online: 13 December 2023 (13:58:03 CET)
A peer-reviewed article of this Preprint also exists.
Buikin, P.A.; Vologzhanina, A.V.; Korlyukov, A.A. Sumatriptan Succinate Hemi(Ethanol Solvate). Molbank 2024, 2024, M1766. Buikin, P.A.; Vologzhanina, A.V.; Korlyukov, A.A. Sumatriptan Succinate Hemi(Ethanol Solvate). Molbank 2024, 2024, M1766.
Abstract
Sumatriptan is a serotonin receptor agonist approved by FDA in 1992 to treat migraines. Its’ solid form used in commercially available drugs Imitrex, Treximet, Onzetra Xsail and Zembrace symtouch is sumatriptan succinate. Herein we report on crystal structure of sumatriptane succinate hemi(ethanol solvate), HSum+·HSucc–·0.5EtOH, its comparison with previously reported solids containing derivatives of sumatriptan.
Keywords
active pharmaceutical ingredient; H-bond propensity; single-crystal X-ray diffraction; sumatriptan
Subject
Chemistry and Materials Science, Medicinal Chemistry
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
